stableBullishPHARMACEUTICALS
FDA Delays Capricor Therapeutics Drug Decision To Review New Data
3 signals from 3 sources·Updated 28 days ago
Momentum
49/100
Affected tickers
CAPR
Summary
The FDA pushed back the decision date for Capricor Therapeutics' drug Deramiocel to November 22, 2026, to incorporate new Phase 3 HOPE-3 data. Sources agree on the delay, though they differ on whether this represents a…
Impact
Contributing sources (3)
- Capricor Therapeutics extends FDA review date for Deramiocel to November 22, 2026 · globenewswire.com · 30 days ago
- FDA delays decision on Capricor Therapeutics' Duchenne muscular dystrophy drug to review data · endpts.com · 30 days ago
- FDA extends review of Capricor Therapeutics drug; Vivek Ramaswamy startup plans IPO · biopharmadive.com · 30 days ago
Get the full Trend Briefing
Impact. Contributing sources. Momentum and affected tickers. Every emerging narrative gets a structured briefing on Whisper Media.
Create your free accountTrend Briefings available on Pro ($69/mo)
Trend Briefings are AI-generated from public sources. They are not financial advice and do not predict outcomes. Always do your own research before making investment decisions.